MX2021013695A - Composición farmacéutica que contiene brexanolona, ganaxolona y zuranolona y usos de esta. - Google Patents

Composición farmacéutica que contiene brexanolona, ganaxolona y zuranolona y usos de esta.

Info

Publication number
MX2021013695A
MX2021013695A MX2021013695A MX2021013695A MX2021013695A MX 2021013695 A MX2021013695 A MX 2021013695A MX 2021013695 A MX2021013695 A MX 2021013695A MX 2021013695 A MX2021013695 A MX 2021013695A MX 2021013695 A MX2021013695 A MX 2021013695A
Authority
MX
Mexico
Prior art keywords
pharmaceutical composition
zuranolone
brexanolone
ganaxolone
composition containing
Prior art date
Application number
MX2021013695A
Other languages
English (en)
Inventor
Lianhong Xu
Robert G Strickley
Zhi Hong
Original Assignee
Brii Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brii Biosciences Inc filed Critical Brii Biosciences Inc
Publication of MX2021013695A publication Critical patent/MX2021013695A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)

Abstract

En la presente se describe una composición farmacéutica que comprende una cantidad farmacéuticamente eficaz de un esteroide neuroactivo que es un modulador positivo de los receptores del ácido ? aminobutírico tipo A (GABAA). También se describen métodos para tratar enfermedades al usar la composición farmacéutica y procesos para producir la composición farmacéutica.
MX2021013695A 2019-05-10 2020-05-08 Composición farmacéutica que contiene brexanolona, ganaxolona y zuranolona y usos de esta. MX2021013695A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962846576P 2019-05-10 2019-05-10
US202063018815P 2020-05-01 2020-05-01
PCT/US2020/032172 WO2020231837A1 (en) 2019-05-10 2020-05-08 Pharmaceutical composition containing brexanolone, ganaxolone, or zuranolone, and use thereof

Publications (1)

Publication Number Publication Date
MX2021013695A true MX2021013695A (es) 2022-01-26

Family

ID=73288816

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021013695A MX2021013695A (es) 2019-05-10 2020-05-08 Composición farmacéutica que contiene brexanolona, ganaxolona y zuranolona y usos de esta.

Country Status (13)

Country Link
US (1) US20220241295A1 (es)
EP (1) EP3965772A4 (es)
JP (1) JP2022532710A (es)
KR (1) KR20220006565A (es)
CN (1) CN113939299A (es)
AU (1) AU2020275291A1 (es)
BR (1) BR112021022527A2 (es)
CA (1) CA3138901A1 (es)
IL (1) IL287905A (es)
MX (1) MX2021013695A (es)
SG (1) SG11202112111WA (es)
TW (2) TW202344255A (es)
WO (1) WO2020231837A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023514873A (ja) * 2020-02-27 2023-04-11 ブリー バイオサイエンシーズ， インコーポレイテッド 神経活性ステロイドのプロドラッグ
TW202227092A (zh) * 2020-08-17 2022-07-16 美商布里生物科學股份有限公司 含有神經活性類固醇之醫藥組合物及其用途
CN112516086B (zh) * 2020-12-08 2022-05-20 武汉久安药物研究院有限公司 注射用布瑞诺龙脂肪乳及其制备方法
WO2022155507A1 (en) * 2021-01-15 2022-07-21 Jubilant Pharma Holdings Inc. Transmucosal dosage forms of brexanolone
US20230149425A1 (en) * 2021-11-18 2023-05-18 Brii Biosciences, Inc. Process and therapeutic composition for treating and preventing severe injection site reactions
US11969434B1 (en) 2022-08-29 2024-04-30 Lipocine Inc. Oral allopregnanolone compositions and methods of use
WO2024085245A1 (ja) * 2022-10-21 2024-04-25 国立大学法人高知大学 術後せん妄の抑制薬
CN115957332B (zh) * 2022-11-01 2023-10-10 北京华睿鼎信科技有限公司 透明质酸酶稳定的布瑞诺龙纳米晶及其制备方法与应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006318349B2 (en) * 2005-11-28 2010-08-19 Marinus Pharmaceuticals Ganaxolone formulations and methods for the making and use thereof
AU2016214996B2 (en) * 2015-02-06 2021-03-04 Marinus Pharmaceuticals, Inc. Intravenous ganaxolone formulations and their use in treating status epilepticus and other seizure disorders
CA3001722A1 (en) * 2015-10-16 2017-04-20 Marinus Pharmaceuticals, Inc. Injectable neurosteroid formulations containing nanoparticles
KR20190137839A (ko) * 2017-04-18 2019-12-11 마리누스 파마슈티컬스 인코포레이티드 지속 방출 주사용 뉴로스테로이드 제제

Also Published As

Publication number Publication date
TWI793419B (zh) 2023-02-21
SG11202112111WA (en) 2021-11-29
AU2020275291A1 (en) 2021-11-25
CA3138901A1 (en) 2020-11-19
BR112021022527A2 (pt) 2021-12-28
KR20220006565A (ko) 2022-01-17
WO2020231837A1 (en) 2020-11-19
EP3965772A4 (en) 2023-05-10
CN113939299A (zh) 2022-01-14
JP2022532710A (ja) 2022-07-19
EP3965772A1 (en) 2022-03-16
TW202108146A (zh) 2021-03-01
IL287905A (en) 2022-01-01
US20220241295A1 (en) 2022-08-04
TW202344255A (zh) 2023-11-16

Similar Documents

Publication Publication Date Title
MX2021013695A (es) Composición farmacéutica que contiene brexanolona, ganaxolona y zuranolona y usos de esta.
MX2021009622A (es) Metodos para tratar la colestasis.
MX2023009611A (es) Esteroides neuroactivos, y su metodo de uso.
WO2020086759A3 (en) Composition and method for treating the lungs
HK1117824A1 (en) Acyloxyalkyl carbamate prodrugs of tranexamic acid and use
WO2019199861A3 (en) Hemp extract for treatment of pain in animals
MY190408A (en) Compositions and methods for treating cns disorders
EA201201403A1 (ru) Очень низкодозированные твердые пероральные лекарственные формы для гзт
MX2009004616A (es) Metodos de tratamiento hormonal que utilizan regimenes de ciclo extendido de dosis ascendente.
BRPI0511569A (pt) composições e métodos para o tratamento de distúrbio disfórico pré-menstrual
RU2011146058A (ru) Способ контрацепции, используемый по мере необходимости
TW200626161A (en) Methods of hormonal treatment utilizing ascending-dose extended cycle regimens
DE60236639D1 (de) Neues verfahren und zusammensetzungen zur örtlichen behandlung von meniere-krankheit, tinnitus und/oder hörverlust
MX2021010972A (es) Forma de dosificacion farmaceutica para la aplicacion a membranas mucosas y metodos para producir las mismas.
MX2022015629A (es) Uso de vibegron para tratar vejiga sobreactiva.
PH12021550965A1 (en) Combination therapy for treatment of hematological diseases
MX2023000187A (es) Dosificacion de vibegron para el tratamiento de vejiga sobreactiva.
MX2021014774A (es) Formulaciones de liberacion modificada y usos de las mismas.
MX2021010568A (es) Leucina, acetilleucina y analogos relacionados para el tratamiento de enfermedades.
WO2019232548A3 (en) Compositions and methods for treating and preventing muscular disorders and dystrophies, steroid side effects, and inflammation
ATE281432T1 (de) C-16 ungesätigte fp-selektive prostaglandin analoge
DE60322852D1 (de) Verfahren zur herstellung von eplerenon
MX2023002649A (es) Nueva formulacion de acido gamma-aminobutirico.
GB2564801A (en) Implantable scaffolds for treatment of sinusitis
CA3168207A1 (en) Cellular uptake